← signals
2026-07-23·TSLA·capex change hyperscaler
highdown

Tesla's Q2 2026 earnings report revealed a significant miss on adjusted EPS ($0.33 vs $0.51 expected) and a negative...

Tesla's Q2 2026 earnings report revealed a significant miss on adjusted EPS ($0.33 vs $0.51 expected) and a negative free cash flow of $1.1B, the first in over two years.

window 10devidence 16confidence score 100price TSLA $391.06

confidence score

Strong evidence: 11 independent source classes support this read.

100
high confidence11 independent source classesnewsofficialotherregionalpasses publish gate
priced-in check

TSLA has not made a large direction-matching 30-90 day move yet.

not priced in
as of 2026-07-167d n/a45d n/a90d -2%yahoo

signal brief

Tesla's Q2 2026 earnings report revealed a significant miss on adjusted EPS ($0.33 vs $0.51 expected) and a negative free cash flow of $1.1B, the first in over two years. Revenue beat at $28.24B, but operating expenses surged 47% to $4.35B, driven by heavy AI and robotics investments. Capital expenditures more than doubled to $5.79B, pushing full-year capex guidance above $25B. Meanwhile, Tesla confirmed delays in volume production for Cybercab, Semi, and Megapack 3—previously expected in 2026. The company also ordered equipment for its TeraFab chip facility, aiming for in-house chip production. Despite record deliveries and EU market share gains, margins compressed to 1.4% operating margin. Stock fell ~4% after hours.

What the sources said:

  • CNBC: 'Tesla reported weaker-than-expected earnings for the second quarter even as revenue topped estimates.' (Source)
  • Reuters: 'Tesla reports a negative Q2 free cash flow of $1.1B ... partly due to increased AI and robotic investments.' (Source)
  • TechCrunch: 'Tesla is no longer planning to reach “volume production” of the Cybercab, the Tesla Semi, and its Megapack 3 in 2026.' (Source)
  • The Economic Times: 'Tesla’s capital expenditures more than doubled ... pushing free cash flow to a negative $1.1 billion.' (Source)

source data used

Decision support, not stock advice. This signal is research with cited evidence — not a recommendation to buy, sell, or hold any security.